VXLLF (Vaxil Bio) Momentum Rank: 10 (As of Sep. 05, 2026) — 67% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VXLLF Vaxil Bio Ltd VXLLF
35 GF Score
Price $0.11
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio Momentum Rank?

Vaxil Bio VXLLF 35 Momentum Rank is 10 as of Sep. 05, 2026, which is 67% above its 10-year median of 6.00. GuruFocus rates VXLLF with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Vaxil Bio has the Momentum Rank of 10.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

VXLLF vs VRTX, REGN, MRNA: Momentum Rank Comparison

For the Biotechnology subindustry, Vaxil Bio's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxil Bio Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxil Bio's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Vaxil Bio's Momentum Rank falls into.


VXLLF
35GF Score
Vaxil Bio Ltd VXLLF
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 10 mean?
Vaxil Bio (VXLLF) has a Momentum Rank of 10 as of Sep. 05, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Vaxil Bio and its competitors. This is 67% above median its historical median of 6.00. Over the past decade, Vaxil Bio's Momentum Rank has ranged from 1.00 to 10.00.
Is Vaxil Bio's Momentum Rank too high?
Vaxil Bio's current Momentum Rank of 10 is 67% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Vaxil Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's Momentum Rank compare to VRTX and REGN?
Vaxil Bio's Momentum Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Vaxil Bio's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Vaxil Bio and its competitors. Vaxil Bio's current Momentum Rank is 10, which is 67% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current Momentum Rank of 10. The current Momentum Rank is 10, which is 67% above median its 10-year median of 6.00. Vaxil Bio's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current Momentum Rank is 10 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXL:Canada
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
35GF Score

Get the complete analysis for VXLLF

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price